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Genetic polymorphisms in DNA repair genes may induce individual variations in DNA repair capacity, which may in turn
contribute to the risk of cancer developing. Homologous recombination repair (HRR) plays a critical role in maintaining
chromosomal integrity and protecting against carcinogenic factors. The aim of the present study was to evaluate the relationship
between prostate cancer risk and the presence of single nucleotide polymorphisms (SNPs) in the genes involved in HRR, that is,
RAD51 (rs1801320 and rs1801321),RAD51B (rs10483813 and rs3784099),XRCC2 (rs3218536), andXRCC3 (rs861539). Polymorphisms
were analyzed by PCR-RFLP and Real-Time PCR in 101 patients with prostate adenocarcinoma and 216 age- and sex-matched
controls. A significant relationship was detected between the RAD51 gene rs1801320 polymorphism and increased prostate cancer
risk. Our results indicate that the RAD51 gene rs1801320 polymorphism may contribute to prostate cancer susceptibility in Poland.
1. Introduction
Prostate cancer (PC) is the secondmost commonly diagnosed
malignant disease in men and the sixth leading cause of
cancer-related death among men worldwide, with an esti-
mated 10948 (14.3%) registered new cases and 4199 (8%)
deaths in 2012 in Poland [1]. Although prostate cancer
is one of the most common cancers in men, the genetic
defects underlying its pathogenesis remain poorly under-
stood. While being over 65 years and the presence of a family
history are the strongest risk factors for prostate cancer,
ethnicity has also been shown to be a risk factor, with the
lowest incidence rates of prostate cancer being observed in
Asian men, particularly in India, China, and Japan. Higher
incidence rates are seen in black men. The risk of developing
prostate cancer is thought to be 1.3–2.0 times higher in
African-American than Caucasian men [2].
Genetic defects in DNA repair and DNA damage res-
ponse genes often lead to an increase of cancer incidence.The
most deleterious form of DNA damage is the DNA double-
strand break (DSB), which can be formed by free radicals
derived from the metabolism, ionizing radiation, or DNA
cross-linking agents or which can naturally occur during
DNA replication. Unrepaired DSBs lead to mutations, rear-
rangements, and/or loss of chromosomes, causing genome
instability and the development of tumors or cell death.
In order to maintain genetic stability, DNA double-strand
breaks must be repaired by homologous recombination or
nonhomologous end-joining.The key protein in homologous
recombination is RAD51, which displaces replication protein
A (RPA) and forms a helical nucleofilament on the exposed
single-stranded DNA flanking the DSB. This nucleofilament
performs a homology search for repair template and then
catalyses DNA strand invasion [3, 4].
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RAD51 is a homologue of the RecA protein and contains
339 amino acids. The RAD51 gene is located at human
chromosome 15q15.1 and is highly polymorphic. Five RAD51
paralogs, that is, RAD51B, RAD51C, RAD51D, XRCC2, and
XRCC3, have been identified in the human genome. They
are key components of homologous recombination, and their
loss can result in the development of genetic instability.
The RAD51 paralogs form two major complexes, RAD51B-
RAD51C-RAD51D-XRCC2 (BCDX2) and RAD51C-XRCC3
(CX3), as well as two subcomplexes, RAD51B-RAD51C (BC)
and RAD51D-XRCC2 (DX2). The CX3 complex is known
to catalyze strand exchange in vitro. Similarly, the BC sub-
complex of the BCDX2 complex has been reported to have
in vitro RAD51 mediator activity and the DX2 subcomplex
has been reported to have strand exchange activity. However,
the specific activities of the RAD51 paralog complexes and
subcomplexes have not been defined in vivo [5–7].
The genetic variations of RAD51 and its paralogs may
contribute to the development of cancer, as has been shown in
the case of breast, ovarian, endometrial, colorectal, and head
and neck cancer and acute leukemia [8–11].
The aim of the work was to evaluate the significance of
common genetic variation in four genes involved in DNA
double-strand break repair via homologous recombination,
that is, RAD51, RAD51B, XRCC2, and XRCC3, in prostate
cancer susceptibility, tagging six most widely studied single
nucleotide polymorphisms (SNPs) in these genes.The associ-
ation between the presence of polymorphisms rs1801320 and
rs1801321 of RAD51, rs10483813 and rs3784099 of RAD51B,
rs3218536 of XRCC2, and rs861539 of XRCC3 and the risk of
prostate cancer was examined.
2. Material and Methods
2.1. Study Subjects. The study included 101 men with prostate
adenocarcinoma and 216 sex- and age-matched persons who
have not been diagnosed with cancer to serve as a control
group. Peripheral blood from the patients with prostate
adenocarcinoma was collected at the 2nd Department of
Urology, Medical University of Lodz, Poland, between Octo-
ber 2009 and December 2011. Peripheral blood from the
control group was obtained from the Maria Sklodowska-
Curie Memorial Hospital, Zgierz, Poland. Blood samples
were collected on EDTA and frozen. The clinical charac-
teristics of the prostate cancer patients and controls are
presented inTable 1. None of the patients underwent any anti-
cancer treatment. The samples were obtained in accordance
with guidelines concerning ethical and legal requirements.
Informed consentwas obtained frompatients, and the studies
were approved by the Independent Ethical Committees of the
Medical University of Lodz, Poland (RNN/59/09/KE), and
the University of Lodz, Poland (KBBN-UŁ/II/25/2012).
2.2. DNA Isolation. DNA was isolated from the blood sam-
ples from the prostate adenocarcinoma patients and controls
using an AxyPrep Blood Genomic DNAMiniprep Kit (Axy-
gen, USA) and the phenol-chloroform method. DNA purity
and quantity were estimated byUV-spectroscopy (Eppendorf
Table 1: Clinical characteristic of studied material.
Prostate cancer patients Control group
Age (year)
Range 49–86 43–84




Mean ± SD 59.96 ± 182.67 1.09 ± 0.88
Median 10.57 0.90
BioPhotometer TM Plus, Eppendorf, Germany). DNA purity
was determined by the 260/280 nm absorbance ratio, with a
value between 1.8 and 2.0 being acceptable.
2.3. Genotyping. Single nucleotide polymorphisms (SNPs) of
the RAD51 (rs1801320 and rs1801321), RAD51B (rs10483813
and rs3784099), XRCC2 (rs3218536), and XRCC3 (rs861539)
genes were analyzed (Table 2).
The genotyping of rs1801320, rs3218536, and rs861539
polymorphisms was determined by PCR-RFLP. The primers
and PCR conditions for the polymorphic sites of these
genes are shown in Table 2. The PCR was run in 10 𝜇L
reactions containing 10 ng of genomic DNA, 0.2mM of each
primer, 2.5mMMgCl
2
, 1 mM deoxyribonucleotide triphos-
phates (dNTPs), 3U HOT FIREPol DNA polymerase, and
1x Solis BioDyne buffer B1. The primers were synthesized
by Sigma-Aldrich (USA), and PCR reagents were obtained
fromSolis BioDyne (Estonia) andAppliedBiosystems (USA).
Thermal cycling was performed as follows: initial activation
at 95∘C for 12min, followed by 30 amplification cycles
consisting of denaturation at 95∘C for 30 s, annealing at
64∘C (rs3218536, rs861539) or 65∘C (rs1801320) for 30 s, and
extension at 72∘C for 1min, followed by a final extension at
72∘C for 10min.
To genotype the rs1801320, rs3218536, and rs861539 poly-
morphisms, 10 𝜇L of each PCR product was digested with
either 2U of MvaI (BstNI) (Thermo Scientific, USA), 1 U
of SexAI (New England Biolabs Inc., USA), or 0.5 units of
NlaIII (New England Biolabs Inc., USA), respectively, for
16 h at 37∘C. The genotypes were determined by running
the digested products in 3% agarose gel with ethidium
bromide (1 𝜇L/mL) for UV visualization. The products for
each genotype of the tested genes are shown in Table 3.
Examples of the obtained restriction patterns are presented
in Figure 1.
The rs1801321, rs10483813, and rs3784099 polymor-
phisms were genotyped by Real-Time PCR (Mastercycler
ep realplex, Eppendorf USA) using TaqMan SNP Geno-
typing Assays (Applied Biosystems). The PCR amplification
was performed according to the manufacturer’s recom-
mendations in 10 𝜇L reactions containing 10 ng of genomic
DNA, 0.25𝜇L SNP Genotyping Assay Mix (40x) (rs1801321
Assay ID: C 7482700 10; rs10483813 Assay ID: C 2564845 10;
rs3784099 Assay ID: C 27481679 10), and 5 𝜇L TaqMan
Universal PCRMasterMix (2x).The amplification conditions
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Table 2: SNPs analyzed.
Gene Polymorphism Other names SNP position Chromosome Global MAF Method
RAD51 rs1801320
c. -98G>C
G135C UTR-5, Exon 15:40695330 13.04% PCR-RFLP
rs1801321 c. -61G>T, G172T UTR-5, Exon 15:40695367 26.63% Real-Time PCR
RAD51B rs10483813 c. 1037-29918T>A Intron 14:68564567 12.49% Real-Time PCR
rs3784099 c. 757-8674G>A Intron 14:68283210 37.79% Real-Time PCR
XRCC2 rs3218536 c. 563G>A, p. Arg188His Missense 7:152648922 4.27% PCR-RFLP
XRCC3 rs861539 c. 722C>T, p. Thr241Met Intron, Missense 14:103699416 25.07% PCR-RFLP
Table 3: Details of PCR-RFLP of the studied SNPs.
SNP Primer sequences Annealingtemp. (∘C)
Product






























GG CCGC GA GG CC TTCT
rs1801320 rs3218536 rs861539
Figure 1: Genotyping of rs1801320, rs3218536, and rs861539 polymorphisms by PCR-RFLP.
consisted of initial AmpliTaq Gold 1 activation at 95∘C for
10min, followed by 40 amplification cycles consisting of
denaturation at 95∘C for 15 s and annealing/extension at 60∘C
for 1min.
2.4. Statistical Analysis. The chi-square test was used to
analyze the Hardy-Weinberg frequencies for the RAD51,
RAD51B, XRCC2, and XRCC3 genotypes in the control and
patients populations. The differences in genotype and allele
frequency between prostate cancer patients and controls were
also evaluated with the chi-square test. The odds ratio (OR)
and corresponding 95% confidence intervals (CI) were deter-
mined through unconditional multiple logistic regression.
Statistical analysis was carried out using Statistica version 9.0
(StatSoft, Poland).
3. Results
The study comprised 101 prostate cancer cases and 216 sex-
and age-matched controls. The genotypes of six genetic
variants of the RAD51, RAD51B, XRCC2, and XRCC3 genes
were determined. The genotypes and allele frequencies for
each polymorphism of the studied genes are summarized in
Table 4.The observed genotype frequencies were found to be
consistent with the Hardy-Weinberg equilibrium at all stud-
ied polymorphic loci, except for the RAD51 polymorphism.
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Table 4: Distribution of genotypes and allele frequency in the RAD51, RAD51B, XRCC2, and XRCC3 loci among prostate cancer patients.
Gene Genotype/allele Prostate cancer patients(𝑛 = 101)
Control group







































C 142 313 0.574
T 60 119
No statistically significant differences were found between
prostate cancer patients and cancer-free controls with regard
to the distribution of genotypes and alleles, apart from the
rs1801320 polymorphism of the RAD51 gene.
The genotype frequencies for each polymorphism, in
both the prostate cancer group and the control group, were
analyzed using a logistic regression model (Table 5). Among
the six polymorphisms examined, the rs1801320 RAD51 gene
polymorphism was found to be significantly associated with
prostate cancer susceptibility. The rs1801320 RAD51 gene
polymorphism was verified by sequencing analysis with
BigDye Terminator Cycle Sequencing Ready Reaction Kits
version 1.1 (see Supplementary Material available online at
http://dx.doi.org/10.1155/2015/828646). Heterozygous (OR =
1.90) and homozygous (OR = 2.98) C genotype variants and
C allele (OR = 2.02, 𝑃 < 0.01) appeared to increase prostate
cancer risk.
The association between the C allele of RAD51 gene
rs1801320 polymorphism and the age and PSAT serum level
of the cancer patientswas analyzed.No statistically significant
relationship was found between the presence of the C allele
for rs1801320 and either age or PSAT serum level (Table 6).
4. Discussion
Despite the high incidence of prostate cancer, the exact cause
of its development is not known. It is assumed that, as in
the case of other cancers, prostate cancer occurs as a result
of the interaction between environmental factors and genetic
predisposition. The standard biomarker associated with
prostate pathology is prostate specific antigen (PSA). PSA is a
kallikrein-like serine protease secreted by the epithelial cells
of the prostate and encoded by an androgen-responsive gene
(19q 13.3–13.4). The major role of PSA is the liquefaction of
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Table 5: Genotype distribution and prostate cancer risk for the RAD51, RAD51B, XRCC2, and XRCC3 polymorphisms in prostate cancer
patients and control group.
Genotype/allele Prostate cancer patients(𝑛 = 101)
Control group
(𝑛 = 216) OR [95% Cl] 𝑃 value
rs1801320
GG 66 (65.3) 172 (79.5) 1 [Ref.]
GC 27 (26.7) 37 (17.3) 1.90 [1.07–3.37] 0.03
CC 8 (8.0) 7 (3.2) 2.98 [1.04–8.54] 0.04
G 159 (78.7) 381 (88.2) 1 [Ref.]
C 43 (21.3) 51 (11.8) 2.02 [1.29–3.16] <0.01
rs1801321
GG 39 (38.6) 67 (31.0) 1 [Ref.]
TG 4 (4.0) 8 (3.7) 0.86 [0.24–3.04] 1
TT 58 (57.4) 141 (65.3) 0.71 [0.43–1.16] 0.17
G 82 (40.6) 142 (32.9) 1 [Ref.]
T 120 (59.4) 290 (67.1) 0.72 [0.51–1.01] 0.06
rs10483813
TT 56 (55.4) 134 (62.0) 1 [Ref.]
TA 40 (39.6) 68 (31.5) 1.41 [0.85–2.32] 0.18
AA 5 (5.0) 14 (6.5) 0.85 [0.29–2.49] 0.78
T 152 (75.2) 336 (77.8) 1 [Ref.]
A 50 (24.8) 96 (22.2) 1.15 [0.78–1.70] 0.48
rs3784099
GG 49 (48.5) 122 (56.5) 1 [Ref.]
GA 41 (40.6) 80 (37.0) 1.28 [0.77–2.11] 0.34
AA 11 (10.9) 14 (6.5) 1.96 [0.83–4.61] 0.12
G 139 (68.8) 324 (75.0) 1 [Ref.]
A 63 (31.2) 108 (25.0) 1.36 [0.94–1.97] 0.10
rs3218536
GG 90 (89) 196 (90.7) 1 [Ref.]
GA 11 (11.0) 20 (9.3) 1.20 [0.55–2.60] 0.65
AA 0 (0.0) 0 (0.0) —
G 191 (94.6) 412 (95.4) 1 [Ref.]
A 11 (5.4) 20 (4.6) 1.19 [0.56–2.53] 0.65
rs861539
CC 54 (53.5) 119 (55.1) 1 [Ref.]
CT 34 (33.7) 75 (34.7) 1.00 [0.60–1.68] 1.00
TT 13 (12.8) 22 (10.2) 1.30 [0.61–2.78] 0.49
C 142 (70.3) 313 (72.5) 1 [Ref.]
T 60 (29.7) 119 (27.5) 1.11 [0.77–1.61] 0.57
Table 6: Relationship between C allele for the RAD51 gene rs1801320 polymorphism and patient’s age and PSAT level.
rs1801320 Age OR [95% Cl] 𝑃 value PSAT OR [95% Cl] 𝑃 value
≤71 >71 <4–10 >10
G 86 16 1 [Ref.] 0.05 77 21 1 [Ref.] 0.88
C 73 27 1.99 [0.99–3.97] 82 22 0.98 [0.50–1.93]
human semen by its proteolytic activity. However, because of
the low specificity of PSA, unnecessary biopsies andmistaken
diagnoses frequently occur. As prostate cancer has a variety
of features, prognosis following diagnosis is greatly variable.
Hence, there is a need for new biomarkers to improve clinical
management of prostate cancer [12].
DNA is replicated with extremely high fidelity in normal
cells, with a mutation rate of 10−10 per base pair per cell
division. DNA damage typically occurs through exposure
to genotoxic chemicals, ultraviolet and ionizing radiation,
failures in normal cellular DNA processing and replication
events (stalled replication forks), and spontaneous DNA-
damaging events. These processes contribute to oxidation,
alkylation, cross-linking, and dimerization and cause strand
breaks in DNA, whose repair is essential for maintaining the
integrity of the genome and preventing cancer. The DNA
double-strand break is the most lethal form of DNA damage,
as it can lead to significant DNAdamage bymultiple genomic
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changes, including translocation, deletion, and amplification,
resulting in heritable cellular genomic instability that can lead
to malignancy [12, 13].
The repair of a double-strand DNA break is performed
by homologous recombination. This process is promoted by
recombinase RAD51, which catalyzes the key reactions that
typify HRR, that is, homology search and DNA strand inva-
sion. Several RAD family members, including its paralogs
RAD51B, XRCC2, and XRCC3, assist RAD51 in this process
[14–16].
There is a growing body of evidence, which suggests
that polymorphic variants of genes involved in DNA repair
could modulate DNA repair capacity and thus have a great
impact on genomic stability and cancer prevention. Human
RAD51 and its paralogs RAD51B, XRCC2, and XRCC3 are
highly polymorphic. The RAD51 polymorphisms c. -98G>C
(rs1801320; 135G>C) and c. -61G>T (rs1801321; 172G>T) are
two of the most common polymorphisms and are located
at 5󸀠UTR. Although the functional consequence of the c.
-98G>C polymorphism is unknown, it is speculated that
because it alters a CpG island pattern in the promoter region,
it may regulate the expression of RAD51 and its mRNA
levels. The c. -61G>T is located in a binding site for the
transcription factor P300/CBP. Current models suggest that
the binding of P300/CBP cofactors to transcription factor
activation domains positions histone acetyltransferases near
specific nucleosomes in the promoter regions of the target
gene. In contrast to the c. -61T allele, the c. -61G allele does
not form a binding site for cis-transcriptional elements for
P300/CBP. Thus, the presence of the T allele results in a
greater effect on RAD51 gene expression [17–19].
It was found that the RAD51 polymorphism rs1801320 is
associated with an elevated risk of breast [20–22] and triple-
negative breast cancer [23] and ovarian [24, 25], endometrial
[26–28], colorectal [9, 29, 30], gastric [31], and head and
neck cancer [32, 33] and myelodysplastic syndrome [34], as
well as keratoconus and Fuchs endothelial corneal dystrophy
[35]. The significance of the RAD51 polymorphism rs1801320
has been best characterized in patients with breast cancer,
especially in carriers of BRCA2 gene mutations. Antoniou
et al. [17] report that the risk of developing breast cancer
increases in the case of a polymorphic variant c. -98G>C and
the presence ofmutations in theBRCA2 gene. No correlations
of this polymorphism were found in carriers of BRCA1 gene
mutations. These results are confirmed by numerous studies
[36–39]. However, on the contrary, Wang et al. [40] observe
that the RAD51 gene rs1801320 polymorphism reduces the
risk of developing ovarian cancer in carriers of the BRCA2
mutations. In addition, Ribeiro Junior et al. [41] indicate that
the rs1801320 polymorphismofRAD51 gene is associatedwith
a decreased risk of developingmyelodysplastic syndrome. No
correlation was found between the presence of the RAD51
rs1801321 polymorphism and the risk of developing endome-
trial and ovarian cancer [28, 42]. However, the variant
c. -61G>T in the RAD51 gene seems to affect the development
of breast and triple-negative breast cancer, acute myeloid
leukemia, and head and neck cancer [32, 43–46].
The RAD51B gene encodes one of five RAD51 paralogs,
which play an important role in DNA repair through
homologous recombination. RAD51B-deficient chicken B
lymphocyte DT40 cells have been observed to impair
homologous recombination and are sensitive to cross-linking
agents. It has been suggested that RAD51B promotes the
assembly of the RAD51 nucleoprotein filaments during
HRR. Inactivation of RAD51B by translocation between
chromosomes 12 and 14 is a frequent finding in uterine
leiomyoma, supporting a role for the inactivation of RAD51B
in tumorigenesis [47]. In the case of the RAD51B gene, a
correlation has been demonstrated between the presence of
the rs3784099 polymorphism and the risk of breast cancer
[48]. The relationship between the RAD51B gene rs10483813
polymorphic variants and risk of triple-negative breast cancer
and age-relatedmacular degeneration has also been indicated
[49, 50].
The XRCC2 and XRCC3 genes are recognized as essential
parts of the homologous recombination repair pathway.They
are required for correct chromosome segregation and apop-
totic response to DSB [51, 52]. A meta-analysis of data from
available literature revealed no direct relationship between
polymorphic variants rs3218536 of the XRCC2 gene and the
risk of breast cancer [53]. However, the XRCC2 Arg188His
polymorphism (c. 563G>A; rs3218536) is suggested tomodify
the risk of breast cancer, including triple-negative breast
cancer [20, 54, 55]. A correlation was found between the
prevalence of the XRCC2 gene rs3218536 polymorphism
and morbidity of triple-negative breast cancer in the female
population in Poland [55]. The XRCC2 gene rs3218536 poly-
morphism has been found to possibly increase the risk of
developing cervical cancer and breast cancer in women in
Pakistan [11, 56]. In contrast, no direct relation was observed
between the occurrence of rs3218536 variant of the XRCC2
gene and the incidence of lung cancer or sporadic colorectal
cancer [57, 58]. Similarly, no correlation has been found with
hereditary colon cancer, known as Lynch syndrome [59].
The Thr241Met substitution is the most thoroughly
analyzed polymorphism in the XRCC3 gene (c. 722C>T;
rs861539). Although the functional relevance of the XRCC3
Thr241Met variation is unknown, some studies have reported
that this polymorphism is associated with increased risk of
breast cancer [20]. A meta-analysis has revealed that the
XRCC3 gene rs861539 polymorphism also increases the risk
of developing hepatocellular carcinoma, as well as head and
neck, bladder, and breast cancer [11, 32, 33, 60–62]. However,
this polymorphism has also been shown to have a weak
association with the risk of breast cancer as well as lung
cancer [63, 64] and no connection with the development
of ovarian, cervical, or colorectal cancer or renal cell car-
cinoma [9, 65–67]. No direct relationship has been found
between the XRCC3 gene rs861539 polymorphism and the
risk of leukemia in the general population. However, studies
performed in Asian populations have implicated it in the risk
of incidence of leukemia [68].
The results of the present study show that the RAD51 gene
rs1801320 polymorphism doubles the risk of prostate cancer
in the studied population. Statistically significant differences
in allele distribution were identified between the control
group and prostate cancer patients (𝑃 < 0.05). Dhillon et
al. [69] do not report any such correlation in an Australian
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population. Hence, the RAD51 gene rs1801320 polymorphism
may act as an independent biomarker of prostate cancer risk
in Polish population.
No associations were found between the polymorphic
variants of the RAD51B, XRCC2, and XRCC3 genes evaluated
in the present study and the susceptibility of prostate cancer.
However, considering that the occurrence of cancer is the
result of complex interactions between genetic changes and
environmental factors, polymorphic variants of the RAD51B,
XRCC2, and XRCC3 genes other than those studied may yet
have an impact on the development of prostate cancer.
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